Newsbenzinga
MiMedx Group Lowers FY2026 Sales Guidance from $260.000M-$290.000M to $250.000M-$260.000M vs $267.018M Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…